baber/WOPTO huggingface dataset:
Patent DE-69034146-D1 (DE)
Inventor: ORLEK BARRY SIDNEY
IPC: A61P25/02
Filed: 1990-04-10
Granted: 2004-07-22
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: <CHEM>  wherein R1 represents <CHEM> in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R2 is a group OR4, where R4 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR5 where R5 is hydrogen or R4, or a group NHR6 or NR7R8 where R6, R7 and R8 are independently C1-2 alkyl; and R3 is chloro, fluoro, bromo, cyclopropyl, C1-3 alkyl substituted by one, two or three halogen atoms, or R3 is a group (CH2)nR9 where R9 is -CN, -OH, -OCH3, -SH, -SCH3, -C IDENTICAL CH or -CH=CH2 and n is 0 or 1, with the proviso that when n is 0, R9 is not -OH or -SH.
Patent DE-69034265-D1 (DE)
Inventor: MONCANY MAURICE
IPC: C12Q1/70
Filed: 1990-06-05
Granted: 2009-04-09
Abstract: Oligonucleotide (I), comprising a specific sequence (A) of the gene gag or gene pol, and susceptible to hybridize at 60[deg]C+-1[deg]C with the genomes of viruses HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 Rod or SIV Mac; or a sequence complementary to a sequence (A), is new. Independent claims are also included for: (1) couple of oligonucleotide primers (II), for carrying out a gene amplification of the gene gag or gene pol of the virus of the type HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 Rod or SIV Ma, where the primers consists each one of: a specific sequence of the gene gag or gene pol, and susceptible to hybridize at 60[deg]C+-1[deg]C with the genomes of viruses HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 Rod or SIV Mac; or a sequence complementary to the sequence (A); (2) a process of gene amplification of nucleic sequences of the gene gag or the gene pol of virus of type (HIV-1 and/or HIV-2, and/or SIV, from a biological sample, comprising: (a) a stage of extraction of the nucleic acid to be detected belonging to the genome of the virus of the HIV-1 type, HIV-2 or SIV, optionally present in the biological sample, and optionally a stage of treatment using a reverse transcriptase of the nucleic acid if the latter is in the form of RNA; (b) a cycle comprising: denaturation of the double stranded nucleic acid to be detected, which leads to the formation of a single strand nucleic acid, hybridization of each strand of nucleic acid, obtained at the stage of denaturation, with at least a primer or a couple of primers of (II), by setting in contact the strands with at least a couple of the primers, formation from primers, of complementary DNA strands on which they are hybridized in the presence of a DNA polymerase and four different nucleosides triphosphate (NTP), which leads to the formation of a greater number of double strand nucleic acid to be detected at the stage of preceding denaturation, and repetition of the cycle for a determined number of times to obtain the nucleic sequence to be detected optionally present in the biological sample in a proportion sufficient to allow its detection; and (c) a stage of detection of the optional presence of the nucleic acid belonging to the genome of the virus in the biological sample; and (3) a kit for carrying out the process of gene amplification of nucleic sequences of the gene gag or the gene pol of virus of type (HIV-1 and/or HIV-2, and/or SIV, from a biological sample, comprising: at least a primer or a couple of oligonucleotidic primers of (II); reagents appropriate to be used in cycle of amplification, in particular DNA polymerase, four different nucleotide triphosphate, and buffer 10X; and one (or several) probe, can be marked, capable of hybridizing with the amplified sequence of nucleic acid to be detected.
Patent DE-69100850-D1 (DE)
Inventor: DE GRAAF MARTIEN
IPC: A01G31/00
Filed: 1991-01-24
Granted: 1994-02-10
Abstract: According to the invention, the bulbs are placed into seats (6) in a felt made of hydrophilic rock wool (5), said seats being spaced regularly and being open on only one side of the felt, where the opening of the seats is slightly smaller than the bulbs (3), and the seats are sufficiently deep so that, when the bulbs (3) are placed in position, they penetrate the seat at least to the level of their maximum cross-section. 
<IMAGE>
Patent DE-69100937-D1 (DE)
Inventor: WADE MALCOLM VICTOR
IPC: F16D35/00
Filed: 1991-10-10
Granted: 1994-02-17
Abstract: A start-up coupling engages progressively in two stages. During the first stage drive is transmitted from an input shaft (3) along respective paths (8,7,9,12,11,10,25 and 26; and, 19,20,19 and 32) to helically-toothed rollers ( 2 7 , 30 ) which mesh but are designed to be incapable of transmitting drive between them, or of doing so very inefficiently. The rollers (27,30) are mounted in an oil-filled chamber (18) in a casing (1) integral with an output shaft (2). During the first hydraulic stage of engagement, oil pockets between their oppositely-moving teeth (28,31) prevent them from engaging as the phase of one roller (27) is progressively changed by a centrifugal adjustment (4) against the bias of a torque cell (19). However, increasing frictional resistance in the oil pockets causes the rollers (27,30) to exert an increasing rotational torque on the casing (1). Simultaneously, the relative movement of the roller teeth diminishes to reduce the hydraulic pressure in the pockets to a level where the pockets collapse. This initiates the second stage of engagement when drive is transmitted through the coupling mechanically by way of rubbing of the roller teeth (28,31). This rubbing ceases when engagement of the coupling is completed. Tooth wear is lessened by the two stages of engagement.
Patent DE-69115249-D1 (DE)
Inventor: PARKER NORMAN
IPC: H01J3/02
Filed: 1991-09-13
Granted: 1996-01-18
Abstract: A cold-cathode field emission device controls electron emission by using a current source coupled to the emitter. The open circuit voltage of the current source is less than the voltage at which the FED would emit electrons. Application of an accelerating potential on the gate enables electron emission. Electron emission from the FED is governed by the current source.
Patent DE-69116224-D1 (DE)
Inventor: UENO RYUJI
IPC: A61P27/02
Filed: 1991-05-21
Granted: 1996-02-22
Abstract: A use of an oculo-hypotensively synergistic combination of     (a) a 13,14-dihydro-15-ketoprostaglandin compound, and   (b) a  beta -adrenergic blocker for the manufacture of a medicament useful in treatment of ocular hypertension. o
Patent DE-69118427-D1 (DE)
Inventor: CICILE JEAN-CHARLES
IPC: B01D53/22
Filed: 1991-03-01
Granted: 1996-05-09
Abstract: The gas mixture (GR) first of all undergoes a compression stage (C1) and then a gas permeation (X1) to extract hydrogen. The hydrogen-free gas phase is condensed (E2) at approximately -20 DEG C to recover a methane-rich gas phase (GNS). The condensed phase is then distilled to separate it into a C2 hydrocarbon-rich fraction and a fraction containing C3 and C4 hydrocarbons (LPG). Use for upgrading oil refinery gases. <IMAGE>
Patent DE-69122608-D1 (DE)
Inventor: GROMAN ERNEST
IPC: G11B5/708
Filed: 1991-02-05
Granted: 1996-11-14
Abstract: This invention relates to compositions comprising a colloidal or particular metal oxide which are stabilized by low molecular weight carbohydrates. The carbohydrates are characterized by the fact that a) they are not retained on the surface of the metal oxide based on the equilibrium room temperature dialysis of about 2 ml of the metal oxide composition at 0.2 M metal concentration against deionized water; and b) they impart sufficient stability to the metal oxide compositions such that the compositions can withstand heat stress without perceptible aggregation as determined by a prescribed test procedure.
Patent DE-69127383-D1 (DE)
Inventor: GUIRGUIS RAOUF A
IPC: A61B5/117
Filed: 1991-01-17
Granted: 1997-10-02
Abstract: A method and device for testing for the presence of substances such as drugs in the blood while simultaneously positively identifying the test subject. The device comprises an absorbent pad (22) and a membrane (24) (preferably a nitro cellulose membrane) mounted to the absorbent pad (22). The absorbent pad (22) preferably contains a plurality of separated areas provided with different absorbed antibody having a specific receptor site for specific antigens produced by different predetermined drugs and a base area without antibodies. The method of testing comprises the steps of: (a) puncturing the finger of a test subject to obtain a quantity of blood on the finger, (b) covering the finger with a thin film of blood (11), (c) placing the finger on a membrane (24) containing antibodies specifically selected to bind antigens produced by the substances being tested for in the blood so that blood is deposited from the finger on the membrane; and (d) adding colour development solution to the membrane (22) to bring out a colour indicating presence or absence of a substance. <IMAGE>
Patent DE-69131133-D1 (DE)
Inventor: HASKILL JOHN
IPC: C12Q1/68
Filed: 1991-09-24
Granted: 1999-05-20
Abstract: <IMAGE>   Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro  beta and  gamma , and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
Patent DE-69132797-D1 (DE)
Inventor: COUDE FRANCOIS-XAVIER
IPC: C07D211/70
Filed: 1991-05-21
Granted: 2001-12-06
Abstract: The invention relates to a method of evaluation of substances which are active at neuronal level, which consists in producing neuronal lesions in experimental animals by injecting an effective amount of vincristine into their medium septum, and in then evaluating the activity of the aforementioned substances in morphological and/or biochemical tests.
Patent DE-69201549-D1 (DE)
Inventor: NAYLOR DONALD BRIAN
IPC: A24B5/16
Filed: 1992-10-09
Granted: 1995-04-06
Abstract: Tobacco leaf stem is separated into large-stem and small-stem fractions, the large-stem fraction is cut in a stem cutter and the small-stem fraction is shredded in a mill, whereafter the cut and shredded materials are mixed.
Patent DE-69215528-D1 (DE)
Inventor: FRIPPIAT ANNE
IPC: A23L27/60
Filed: 1992-10-02
Granted: 1997-01-09
Abstract: PCT No. PCT/BE92/00042 Sec. 371 Date Jun. 6, 1994 Sec. 102(e) Date Jun. 6, 1994 PCT Filed Oct. 2, 1992 PCT Pub. No. WO93/06744 PCT Pub. Date Apr. 15, 1994.Compositions having a creamy structure and containing a fructane or fructanes mixed with a liquid such as water, milk, egg white, egg yolk or sugar syrup; and the use of said compositions in foodstuffs such as ice cream, salad dressings, chocolate preparations, meat products, breads and pastries, fillings, sandwich spreads, jam, dairy products, sauces, etc. The foods containing these compositions are also described.
Patent DE-69218034-D1 (DE)
Inventor: OZAKI EIJI
IPC: C12P11/00
Filed: 1992-05-15
Granted: 1997-04-17
Abstract: The present invention relates to a DNA fragment containing a nucleotide sequence that encodes an amino acid sequence of esterase, said esterase asymmetrically hydrolyzing carboxylic acid esters represented by the formula (I); <CHEM> (wherein R1 is alkyl, aralkyl or aryl, R2 and R3 are alkyl, and n is 1 or 2) an esterase encoded by the DNA fragment, a recombinant plasmid containing the DNA fragment, a microorganism transformed with the recombinant plasmid and methods of producing optically active carboxylic acids and their enantiomeric esters.
Patent DE-69221837-D1 (DE)
Inventor: AEBISCHER PATRICK
IPC: C12N11/00
Filed: 1992-06-25
Granted: 1997-10-02
Abstract: Methods and devices are disclosed for the delivery of an active factor from an implanted co-culture of an active factor-secreting cell obtained from a first source and an augmentary substance-secreting cell obtained from a second source different from the first source, to a target region in a subject. The co-culture is maintained within a biocompatible, semipermeable membrane in which the augmentary substance secreted by the augmentary substance-producing cells stimulates the active factor-producing cells to secrete active factor. The semipermeable membrane permits the diffusion of the active factor therethrough while excluding detrimental agents present in the extenral environment from gaining access to the co-culture.
Patent DE-69229538-D1 (DE)
Inventor: RUSSELL STEPHEN RONALD
IPC: G09B25/02
Filed: 1992-11-24
Granted: 1999-08-12
Abstract: A device for simulating electrical characteristics of an electrical, electronic or electromechanical component comprising means 21 adapted to reproduce electrical characteristics which are produced by, or may be sensed in, the component, the device 1 being configured so as to substantially resemble the component in appearance and/or size. The device may have two substantially flat opposed surfaces 3,27, one of which carries a picture 5 of the component and the other a sectional view through the component to illustrate its technical construction or operation, and/or other data relating to the component. A kit may be provided comprising a number of such devices each to simulate a component forming part of an equipment or system so as to simulate the electrical characteristics and/or performance of the equipment or system. <IMAGE>
Patent DE-69304620-D1 (DE)
Inventor: WRANGBERTH JAN STELLAN
IPC: A47L15/42
Filed: 1993-06-11
Granted: 1996-10-17
Abstract: This invention relates to a device for a dishwasher comprising a chassis with a treatment chamber (16) for dish, one side wall of the treatment chamber being provided with an opening through which the dish is inserted into and is taken out from the treatment chamber. The opening is normally covered by a door (17) which is pivotally supported at its lower horizontal edge so that the door from its normally closed, vertical position can be turned to a mainly horizontal position. The dishwasher is a so called built-in machine with the door (17) comprising an outer door (18), for example with a panel, whose peripheral parts (19) facing the treatment chamber are placed adjacent the front edge (20) of a cabinet shell surrounding the chassis (21) when the door is in its vertical position. The lower edge of the outer door (18) is during the movement of the door allways situated in front of the vertical plane which is defined by the front edges (20) of the cabinet shell. <IMAGE>
Patent DE-69306095-D1 (DE)
Inventor: VAN HELMOND JOHANNES
IPC: E04G7/30
Filed: 1993-12-09
Granted: 1997-01-02
Abstract: A scaffolding construction, in particular comprising H-shaped frames. The posts (1) of a frame are provided at the one end (4) with a bushing (5), of which the inner diameter is larger than the outer diameter of the post (1). The bushing (5) is provided with a recess (7) and with a staggered groove (8) lying opposite to it. The other end of a post (1) is provided with a pin (14) which can be fittingly received in the groove (8) and in the upper end of a post (8). In the horizontal position of the posts, its pins are inserted in the groove (8) via the recesses (7). During the angular rotation which the post (1) carries out while being swung into its vertical position, the pins (14) are guided by the grooves (8), and the posts by the recesses (7), so that so that the pins come to rest in the posts. <IMAGE>
Patent DE-69310763-D1 (DE)
Inventor: THOMSON JAMES
IPC: C23C16/18
Filed: 1993-11-19
Granted: 1997-06-19
Abstract: There is described a method of chemically depositing a substance. The method is of utility in the direct manufacture of integrated circuits and in the manufacture of a photomask for use in production of integrated circuits. The method involves the use of a compound which degrades into a deposit and a residue when a radiant beam (e.g. a laser beam) or a particle beam (e.g. an electron beam) is applied. The residue and any unreacted compound may be washed off the substrate to which it has been applied. Nanoscale dimensions of the deposit can be achieved. A particularly suitable organometallic compound is tetra-sec butyl diaurum difluoride.
Patent DE-69322151-D1 (DE)
Inventor: MENEGAZZI PASCAL
IPC: G01N23/04
Filed: 1993-12-21
Granted: 1998-12-24
Abstract: The present invention relates to the reconstitution of volumes normally located inside a solid with a view to carrying out calculations relating to the said volume. According to the invention, the method essentially consists in:   a) making digitized images of several parallel sections of the space neighbouring the said volume, b) processing the said data in order to numerically create a contour of the said volume, and c) processing the data relating to the said contour in order to make them usable for essentially numerical calculations.   The invention relates, in particular, to the application of the method to reconstituting a cooling circuit of an internal combustion engine cylinder head. <IMAGE>
Patent DE-69324614-D1 (DE)
Inventor: GREENFIELD WALTER
IPC: G01N1/28
Filed: 1993-05-18
Granted: 1999-05-27
Abstract: The invention relates to a reusable slide assembly for use in combination with an apparatus for drawing a fluid specimen sample for analysis from a sample tube into said slide assembly. Such apparatus and technique are used in urinalysis.
Patent DE-69325711-D1 (DE)
Inventor: TURUNEN OLLI
IPC: D01F6/04
Filed: 1993-05-28
Granted: 1999-08-26
Abstract: PCT No. PCT/FI93/00230 Sec. 371 Date Dec. 16, 1994 Sec. 102(e) Date Dec. 16, 1994 PCT Filed May 28, 1993 PCT Pub. No. WO93/24686 PCT Pub. Date Dec. 9, 1993.The invention concerns a high strength polyethylene fibre, which is prepared by melt spinning polyethylene having a high density through a spinnerette, by cooling the fibre coming out from the spinnerette and by stretching the fibre obtained at 50 DEG -150 DEG  C. The polyethylene used in the melt spinning is a homopolymer of ethylene having a weight average molecular weight Mw between 125000-175000 g/mol, a number average molecular weight Mn between 26000-33000 g/mol, polydispersity (Mw/Mn) below 5 and the density higher than 955 g/dm3. The stretching degree in the drawing step is at least 400%.
Patent DE-69327801-D1 (DE)
Inventor: BENGTSSON RAYMOND
IPC: G03B21/64
Filed: 1993-10-11
Granted: 2000-03-09
Abstract: PCT No. PCT/SE93/00823 Sec. 371 Date Apr. 12, 1995 Sec. 102(e) Date Apr. 12, 1995 PCT Filed Oct. 11, 1993 PCT Pub. No. WO94/09406 PCT Pub. Date Apr. 28, 1994This invention relates to an overhead transparency storage and presentation pocket. The pocket has two sheets of material that are welded together along two mutually adjacent edges. Alternatively, the pocket is a folded sheet of material welded along one edge. Attached to the upper or lower sheet is at least one colored and light-permeable or light-dampening flap, which is intended to color the light gap which otherwise normally occurs when presenting an overhead transparency of known standard size with the aid of an overhead projector.
Patent DE-69328128-D1 (DE)
Inventor: NAKAGAMI HIROAKI
IPC: A61K9/10
Filed: 1993-10-27
Granted: 2000-04-20
Abstract: A granular pharmaceutical preparation prepared by granulating finely powdered Ebselen(2-phenyl-1,2-benzisoselenazol-3(2H)-one) using a hydrophilic polymer, and an aqueous suspension thereof. The Ebselen granular pharmaceutical preparation of the present invention is excellent in its performance as an oral preparation for use in stomach tube administration. That is, since it can be dispersed easily and uniformly when suspended in water or an aqueous solution before its use, and the suspension can be maintained in excellent dispersed state, preparation and tube administration of the drug solution can be made easily. Also, its dose is accurate because the administration can be effected with no drug or drug solution remained in the tube after the administration. In addition, the granular pharmaceutical preparation of the present invention is also suited for its large scale production, because it can be produced without employing special apparatuses and production steps.
Patent DE-69401936-D1 (DE)
Inventor: KVASNES OLAV JOHAN SILSETH
IPC: E05D15/10
Filed: 1994-05-06
Granted: 1997-04-10
Abstract: The sliding door is secured by a locking mechanism in a closed position wherein the sliding panel is held against a frame. When the locking mechanism is released, the weight of the sliding door causes the panel to move away from the frame while tilting the wheels in which the sliding panel slides into tilted positions. The panel is then free to roll along guide rails on the tilted wheels. When in the closed position, seals on the movable panel seal against the frame. During travel of the panel, the seals are in spaced relation to the frame.
Patent DE-69402179-D1 (DE)
Inventor: MOGENSEN ERLING KRISTEN
IPC: B65D19/42
Filed: 1994-01-14
Granted: 1997-04-24
Abstract: PCT No. PCT/DK94/00024 Sec. 371 Date Aug. 4, 1995 Sec. 102(e) Date Aug. 4, 1995 PCT Filed Jan. 14, 1994 PCT Pub. No. WO94/15845 PCT Pub. Date Jul. 21, 1994A container base (5) is adapted to receive various types of side-boards owing to a new corner structure. The corner structure is characterized in that coupling means can be inserted in two mutually perpendicular horizontal directions and in a vertical direction. This is achieved in that a pair of pipe profiles (10, 11) has open ends to receive coupling means, and by the provision of a further pipe profile (12) which extends perpendicularly to the pipe profiles (10, 11). The further pipe section is terminated at the same level as or below the lower side wall of the substantially horizontal pipe parts and is secure to the lower wall edges of these. All pipe profiles are located in such a way that they do not prevent introduction of a coupling means into any of the pipe profiles of the corner.
Patent DE-69413238-D1 (DE)
Title: Indolderivate als thromboxane a2 antagonisten
Inventor: CROSS PETER EDWARD
IPC: A61K31/44
Filed: 1994-08-09
Granted: 1998-10-15
Abstract: PCT No. PCT/EP94/02660 Sec. 371 Date Feb. 23, 1996 Sec. 102(e) Date Feb. 23, 1996 PCT Filed Aug. 9, 1994 PCT Pub. No. WO95/06046 PCT Pub. Date Mar. 2, 1995Compounds of formula (I):    <IMAGE>  (I)  and pharmaceutically acceptable salt and biolabile esters thereof, wherein R1 is H, C1-C4 alkyl, phenyl optionally substituted by up to three substituents independently selected from C1-C4 alkyl, C1-C4 alkoxy, halogen and CF3, or is 1-imidazolyl, 3-pyridyl or 4-pyridyl; R2 is H or C1-C4 alkyl, R3 is SO2R4 or COR4where R4 is C1-C6 alkyl, C1-C3 perfluoroalkyl(CH2)p, C3-C6 cycloalkyl(CH2)p, aryl(CH2)p, or heteroaryl(CH2)p, p being 0, 1 or 2, or R4 may be NR5R6 where R5 is H or C1-C4 alkyl and R6 is C1-C6, alkyl, C3-C6 cycloalkyl or aryl, or R5 and R6 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further heteroatom linkage selected from O, S, NH, N(C1-C4 alkyl) and N(C1-C5 alkanoyl); X is CH2 or a direct link, with the proviso that when R1 is 1-imidazolyl then X is CH2; m is 2, or 3; n is 0, 1 or 2, and wherein the group (CH2)nNHR3 is attached at the 5-position when n is 0 or 1, or at the 5- or 4-position when n is 2. These compounds are selective TXA2 and PGH2 antagonists. Some also inhibit thromboxane synthetase.